Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Ligand Pharmaceuticals, Inc. Snapshot | 6 | 1 |
| Ligand Pharmaceuticals, Inc. Overview | 6 | 1 |
| Key Information | 6 | 1 |
| Key Facts | 6 | 1 |
| Ligand Pharmaceuticals, Inc. Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| Ligand Pharmaceuticals, Inc. Pipeline Review | 10 | 9 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| Pipeline Products Partnered Products | 12 | 1 |
| Partnered Products/Combination Treatment Modalities | 13 | 3 |
| Pipeline Products Out-Licensed Products | 16 | 1 |
| Out-Licensed Products/Combination Treatment Modalities | 17 | 2 |
| Ligand Pharmaceuticals, Inc. Pipeline Products Glance | 19 | 5 |
| Ligand Pharmaceuticals, Inc. Late Stage Pipeline Products | 19 | 1 |
| Pre-Registration Products/Combination Treatment Modalities | 19 | 1 |
| Phase III Products/Combination Treatment Modalities | 20 | 1 |
| Ligand Pharmaceuticals, Inc. Clinical Stage Pipeline Products | 21 | 1 |
| Phase II Products/Combination Treatment Modalities | 21 | 1 |
| Phase I Products/Combination Treatment Modalities | 22 | 1 |
| Ligand Pharmaceuticals, Inc. Early Stage Pipeline Products | 23 | 1 |
| Preclinical Products/Combination Treatment Modalities | 23 | 1 |
| Ligand Pharmaceuticals, Inc. Drug Profiles | 24 | 16 |
| lasofoxifene tartrate | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 2 |
| clopidogrel bisulfate | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 2 |
| aplindore fumarate | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| pradefovir mesylate | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 1 |
| MB-07133 | 30 | 1 |
| Product Description | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| R&D Progress | 30 | 1 |
| LGD-6972 | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| Drug to Inhibit JAK3 for Inflammation | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| LG-7455 | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| LGD-3437 | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| LGD-7501 | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 1 |
| PS-031291 | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| Small Molecule to Antagonize CCR1 for Oncology | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| Small Molecules to Activate Glucokinase for Type 2 Diabetes | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| Ligand Pharmaceuticals, Inc. Pipeline Analysis | 40 | 6 |
| Ligand Pharmaceuticals, Inc. Pipeline Products by Target | 40 | 2 |
| Ligand Pharmaceuticals, Inc. Pipeline Products by Route of Administration | 42 | 1 |
| Ligand Pharmaceuticals, Inc. Pipeline Products by Molecule Type | 43 | 1 |
| Ligand Pharmaceuticals, Inc. Pipeline Products by Mechanism of Action | 44 | 2 |
| Ligand Pharmaceuticals, Inc. Recent Pipeline Updates | 46 | 5 |
| Ligand Pharmaceuticals, Inc. Dormant Projects | 51 | 1 |
| Ligand Pharmaceuticals, Inc. Discontinued Pipeline Products | 52 | 3 |
| Discontinued Pipeline Product Profiles | 52 | 1 |
| adipiplon | 52 | 1 |
| clopidogrel bisulfate | 52 | 1 |
| LGD-5552 | 52 | 1 |
| managlinat dialanetil | 52 | 1 |
| NGD-2000-1 | 53 | 1 |
| NGD-91-1 | 53 | 1 |
| NGD-91-2 | 53 | 1 |
| NGD-91-3 | 53 | 1 |
| NGD-94-1 | 53 | 1 |
| NGD-94-4 | 53 | 1 |
| NGD-96-1 | 53 | 1 |
| NGD-97-1 | 53 | 1 |
| Vanilloid Receptor-1 Program | 54 | 1 |
| Ligand Pharmaceuticals, Inc. Company Statement | 55 | 1 |
| Ligand Pharmaceuticals, Inc. Locations And Subsidiaries | 56 | 2 |
| Head Office | 56 | 1 |
| Other Locations &Subsidiaries | 56 | 2 |
| Appendix | 58 | 2 |
| Methodology | 58 | 1 |
| Coverage | 58 | 1 |
| Secondary Research | 58 | 1 |
| Primary Research | 58 | 1 |
| Expert Panel Validation | 58 | 1 |
| Contact Us | 58 | 1 |
| Disclaimer | 59 | 1 |